Abstract
Background: To date, only a few comparisons between subcutaneous implantable cardioverter-defibrillator (S-ICD) patients undergoing and those not undergoing defibrillation testing (DT) at implantation (DT+ vs DT–) have been reported. Objective: The purpose of this study was to compare long-term clinical outcomes of 2 propensity-matched cohorts of DT+ and DT– patients. Methods: Among consecutive S-ICD patients implanted across 17 centers from January 2015 to October 2020, DT– patients were 1:1 propensity-matched for baseline characteristics with DT+ patients. The primary outcome was a composite of ineffective shocks and cardiovascular mortality. Appropriate and inappropriate shock rates were deemed secondary outcomes. Results: Among 1290 patients, a total of 566 propensity-matched patients (283 DT+; 283 DT–) served as study population. Over median follow-up of 25.3 months, no significant differences in primary outcome event rates were found (10 DT+ vs 14 DT–; P =.404) as well as for ineffective shocks (5 DT– vs 3 DT+; P =.725). At multivariable Cox regression analysis, DT performance was associated with a reduction of neither the primary combined outcome nor ineffective shocks at follow-up. A high PRAETORIAN score was positively associated with both the primary outcome (hazard ratio 3.976; confidence interval 1.339–11.802; P =.013) and ineffective shocks alone at follow-up (hazard ratio 19.030; confidence interval 4.752–76.203; P =.003). Conclusion: In 2 cohorts of strictly propensity-matched patients, DT performance was not associated with significant differences in cardiovascular mortality and ineffective shocks. The PRAETORIAN score is capable of correctly identifying a large percentage of patients at risk for ineffective shock conversion in both cohorts.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Heart Rhythm |
| Jahrgang | 18 |
| Ausgabenummer | 12 |
| Seiten (von - bis) | 2072-2079 |
| Seitenumfang | 8 |
| ISSN | 1547-5271 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 12.2021 |
Fördermittel
Funding sources: The authors have no funding sources to disclose. Disclosures: Dr Santini is a consultant/speaker for Boston Scientific. Dr Tondo is a member of the Boston Scientific Advisory Board. Dr Steffel has received consultant and/or speaker fees Boston Scientific; and has received grant support through his institution from Boston Scientific. Dr Luigi Di Biase is a consultant for Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Zentren: Universitäres Herzzentrum Lübeck (UHZL)
DFG-Fachsystematik
- 2.22-12 Kardiologie, Angiologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver